ES2103756T3 - Deteccion de metabolizadores ineficaces de farmacos. - Google Patents

Deteccion de metabolizadores ineficaces de farmacos.

Info

Publication number
ES2103756T3
ES2103756T3 ES91108867T ES91108867T ES2103756T3 ES 2103756 T3 ES2103756 T3 ES 2103756T3 ES 91108867 T ES91108867 T ES 91108867T ES 91108867 T ES91108867 T ES 91108867T ES 2103756 T3 ES2103756 T3 ES 2103756T3
Authority
ES
Spain
Prior art keywords
detection
metabolizers
ineffective
pharmaceutical
responsible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91108867T
Other languages
English (en)
Inventor
Urs Albert Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26127843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103756(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2103756T3 publication Critical patent/ES2103756T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

UN METODO PARA LA DETECCION DE METABOLIZANTES POBRES DE DROGAS UTILIZANDO TECNOLOGIA PCR COMO SE DESCRIBE INCLUYENDO A) AMPLIFICAR OPCIONALMENTE UNA CODIFICACION DE GEN PARA UNA ENZIMA DE LA QUE SE SABE QUE ES RESPONSABLE DE LA METABOLIZACION DE MEDICAMENTOS, SEPARANDOLA DE ESTE MODO DE SEUDOGENES RELACIONADOS POSIBLEMENTE CERCANOS, B) AMPLIFICAR DIFERENTES FORMAS ALELICAS DEL GEN DEL PASO A) Y C) DETECTAR EL PRODUCTO DEL PASO B). TAMBIEN SE DESCRIBEN LOS ELEMENTOS PRIMARIOS PARA LA AMPLIACION DE GENES QUE CODIFICAN LAS ENZIMAS METABOLIZANTES DE DROGAS, ESPECIALMENTE LOS GENES QUE CODIFICAN LAS ENZIMAS RESPONSABLES DE DEBRISOQUINA O ACETILACION FENOTIPO.
ES91108867T 1990-06-22 1991-05-29 Deteccion de metabolizadores ineficaces de farmacos. Expired - Lifetime ES2103756T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90810467 1990-06-22
EP91108867A EP0463395B1 (en) 1990-06-22 1991-05-29 Detection of poor metabolizers of drugs

Publications (1)

Publication Number Publication Date
ES2103756T3 true ES2103756T3 (es) 1997-10-01

Family

ID=26127843

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91108867T Expired - Lifetime ES2103756T3 (es) 1990-06-22 1991-05-29 Deteccion de metabolizadores ineficaces de farmacos.

Country Status (8)

Country Link
US (1) US5648482A (es)
EP (1) EP0463395B1 (es)
JP (1) JP3372044B2 (es)
AU (1) AU645091B2 (es)
CA (1) CA2045012C (es)
DE (1) DE69126064T2 (es)
ES (1) ES2103756T3 (es)
NZ (1) NZ238610A (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001181D0 (en) * 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
JPH05260980A (ja) * 1992-03-23 1993-10-12 Tokyo Met Gov Shinkei Kagaku Sogo Kenkyusho ヒト・アリルアミンｎ−アセチル転移酵素遺伝子
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US7115364B1 (en) 1993-10-26 2006-10-03 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US20060229824A1 (en) 1993-10-26 2006-10-12 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes
US6306348B1 (en) * 1993-11-01 2001-10-23 Nanogen, Inc. Inorganic permeation layer for micro-electric device
JP3564579B2 (ja) * 1994-05-06 2004-09-15 大塚製薬株式会社 ヒトチトクロームｐ４５０２ｄ６遺伝子多型の検出方法
US5643723A (en) * 1994-05-26 1997-07-01 Roche Molecular Systems, Inc. Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens
US5719026A (en) * 1994-07-06 1998-02-17 Otsuka Pharmaceutical Co., Ltd. Method for detecting polymorphism of human cytochrome P4501A2 gene
US6048734A (en) 1995-09-15 2000-04-11 The Regents Of The University Of Michigan Thermal microvalves in a fluid flow method
US6391550B1 (en) 1996-09-19 2002-05-21 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
US6183963B1 (en) * 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay
US7135283B1 (en) * 1998-11-17 2006-11-14 Nanogen, Inc. Topoisomerase type II gene polymorphisms and their use in identifying drug resistance and pathogenic strains of microorganisms
GB9828619D0 (en) * 1998-12-23 1999-02-17 Janssen Pharmaceutica Nv An assay for genotyping cytochrome expression
JP2003521024A (ja) * 1999-06-25 2003-07-08 ジェネサンス・ファーマシューティカルズ・インコーポレーテッド ハプロタイプデータの入手および使用のための方法
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
WO2001023082A2 (en) * 1999-09-30 2001-04-05 Nanogen, Inc. Biomolecular attachment sites on microelectronic arrays
US6303082B1 (en) * 1999-12-15 2001-10-16 Nanogen, Inc. Permeation layer attachment chemistry and method
US7250252B2 (en) 1999-12-30 2007-07-31 David Aaron Katz Amplification based polymorphism detection
CA2397340A1 (en) * 2000-01-14 2001-07-19 Incyte Genomics, Inc. Drug metabolizing enzymes
JP2003522528A (ja) * 2000-02-11 2003-07-29 インサイト・ゲノミックス・インコーポレイテッド 薬剤代謝酵素
WO2001079468A2 (en) * 2000-04-13 2001-10-25 Incyte Genomics, Inc. Drug metabolizing enzymes
AU2001255448A1 (en) * 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
US7229756B1 (en) 2000-10-19 2007-06-12 University Of Cincinnati Alpha-2B-adrenergic receptor polymorphisms
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US7211386B2 (en) * 2000-08-10 2007-05-01 University Of Cincinnati Alpha-2A-adrenergic receptor polymorphisms
GB0021286D0 (en) * 2000-08-30 2000-10-18 Gemini Genomics Ab Identification of drug metabolic capacity
CA2423694A1 (en) * 2000-09-29 2002-04-04 Incyte Genomics, Inc. Transferases
WO2002026988A2 (en) * 2000-09-29 2002-04-04 Incyte Genomics, Inc. Human drug metabolizing enzymes
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
US20030170651A1 (en) * 2001-06-05 2003-09-11 Marco Guida Method of identifying a polymorphism in CYP2D6
US8067556B2 (en) * 2001-07-26 2011-11-29 Agilent Technologies, Inc. Multi-site mutagenesis
US6960298B2 (en) * 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US20040267458A1 (en) * 2001-12-21 2004-12-30 Judson Richard S. Methods for obtaining and using haplotype data
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US20040091909A1 (en) * 2002-07-05 2004-05-13 Huang Doug Hui High throughput cytochrome P450 genotyping
US8394944B2 (en) * 2002-09-20 2013-03-12 Siemens Healthcare Diagnostics Inc. Dual-purpose primers and probes for providing enhanced hybridization assays by disruption of secondary structure formation
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
WO2004094986A2 (en) * 2003-04-16 2004-11-04 Handylab, Inc. System and method for electrochemical detection of biological compounds
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
JP2008504826A (ja) * 2004-06-30 2008-02-21 ティーエム バイオサイエンス ピージーエクス インコーポレイティッド チトクロムｐ４５０−２ｄ６をコードする遺伝子における変異を検出する方法
ES2345993T3 (es) 2004-09-14 2010-10-07 The Regents Of The University Of Colorado, A Body Corporate Metodo para el tratamiento con bucindolol basado en direccionamiento genetico.
US7572586B2 (en) * 2005-11-01 2009-08-11 Mayo Foundation For Medical Education And Research Identifying susceptibility to cardiac hypertrophy
EP1958111A4 (en) * 2005-11-29 2009-07-08 Childrens Hosp Medical Center OPTIMIZATION AND INDIVIDUALIZATION OF THE SELECTION AND DOSAGE OF MEDICAMENTS
US7687103B2 (en) * 2006-08-31 2010-03-30 Gamida For Life B.V. Compositions and methods for preserving permeation layers for use on active electronic matrix devices
WO2008076856A2 (en) * 2006-12-14 2008-06-26 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting cyp2d6 polymorphisms
JP2010526102A (ja) * 2007-05-04 2010-07-29 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の制御放出経口製剤および不整脈を予防するための関連する方法
CN102876775A (zh) * 2012-05-03 2013-01-16 骆子义 用实时荧光定量pcr检测nat2基因多态性的试剂盒及方法
CN114317533B (zh) * 2022-01-12 2023-08-29 武汉艾迪康医学检验所有限公司 一组探针和利用杂交捕获法检测药物基因组学相关基因cyp2d6多态性的建库试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US292815A (en) * 1884-02-05 William hofeb
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1338457C (en) * 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
CA1317535C (en) * 1987-06-30 1993-05-11 Nanibhushan Dattagupta Assay of sequences using amplified genes
IE61148B1 (en) * 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5508199A (en) * 1989-01-03 1996-04-16 The United States Of America As Represented By The Department Of Health And Human Services P450db1 clones for identifying humans with genetic defect in drug metabolism

Also Published As

Publication number Publication date
NZ238610A (en) 1993-11-25
JPH05211895A (ja) 1993-08-24
CA2045012A1 (en) 1991-12-23
JP3372044B2 (ja) 2003-01-27
AU645091B2 (en) 1994-01-06
EP0463395B1 (en) 1997-05-14
AU7848791A (en) 1992-01-02
EP0463395A1 (en) 1992-01-02
CA2045012C (en) 2005-10-18
DE69126064D1 (de) 1997-06-19
DE69126064T2 (de) 1997-08-28
US5648482A (en) 1997-07-15

Similar Documents

Publication Publication Date Title
CA2045012A1 (en) Detection of poor metabolizers of drugs
Di Caprio et al. Anti‐inflammatory properties of low and high doxycycline doses: an in vitro study
WO2001088190A3 (en) Poly-primed amplification of nucleic acid sequences
MX2022014230A (es) Conjugados de anticuerpo-farmaco que comprenden agonistas de sting.
FI934849A0 (fi) Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser
ES2127203T3 (es) Vacunas y metodos para su produccion.
ES2113448T3 (es) Catalizador de polimerizacion de olefinas, procedimiento para su preparacion y su utilizacion.
ES2191192T3 (es) Tienopirimidinas.
DK0693924T4 (da) Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
ES2137164T3 (es) Procedimiento para detectar un acido nucleico diana en una muestra.
CA960211A (en) PROCESS FOR THE PREPARATION OF NEW .alpha.-AMINOPENICILLINS AND SUCH PENICILLINS, AND INTERMEDIATES AND PHARMACEUTICAL PREPARATIONS
NO20093014L (no) Taxanderivater og fremgangsmater ved fremstilling derav
PH11788A (en) Dihydroxyhexahydrodibenzo(b.d)pyrans derivatives,pharmaceutical composition and method of use thereof
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
ES2167748T3 (es) Derivados del polisacarido k5 con actividad anticoagulante.
ES2114525T3 (es) Uso de cebadores oligonucleotidicos conservados para la amplificacion de las secuencias de adn del virus de papiloma humano.
ES2051695T3 (es) Tratamiento de la trombosis que contiene un fibrinolitico y un analogo de carbaciclina.
ATE334670T1 (de) Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen
NO934720L (no) Nye HIV protease inhibitorer
ES2120962T3 (es) Composicion antivirica.
ES2073483T3 (es) Derivados del cromano.
ES2148164T3 (es) Cepa atenuada de vacuna del virus del sarampion, que contiene una secuencia nucleotidica especifica y procedimiento para su identificacion.
DK1611252T3 (da) In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren
Akaishi Comparison of insertion, deletion, and point mutations in the genomes of human adenovirus HAdvC-2 and SARS-CoV-2
IT1284873B1 (it) Derivati stabili di ubichinolo procedimenti per la loro produzione e loro impiego farmaceutico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 463395

Country of ref document: ES